Sionna Therapeutics (NASDAQ:SION) Earns “Buy” Rating from BTIG Research

Sionna Therapeutics (NASDAQ:SION)‘s stock had its “buy” rating reaffirmed by stock analysts at BTIG Research in a research note issued to investors on Monday,Benzinga reports. They currently have a $58.00 price target on the stock. BTIG Research’s target price would suggest a potential upside of 51.91% from the company’s current price.

SION has been the topic of a number of other reports. Guggenheim upped their target price on Sionna Therapeutics from $45.00 to $50.00 and gave the company a “buy” rating in a research report on Monday, March 2nd. Lifesci Capital raised Sionna Therapeutics to a “strong-buy” rating in a research report on Wednesday, February 25th. Raymond James Financial restated a “strong-buy” rating and set a $53.00 price objective on shares of Sionna Therapeutics in a research note on Monday, January 5th. Citizens Jmp began coverage on Sionna Therapeutics in a research note on Tuesday, February 24th. They set a “market outperform” rating and a $63.00 price objective on the stock. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Sionna Therapeutics in a research note on Monday, December 29th. Two analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, Sionna Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $50.57.

Sionna Therapeutics Trading Up 0.2%

SION traded up $0.07 during midday trading on Monday, hitting $38.18. The company’s stock had a trading volume of 470,495 shares, compared to its average volume of 335,123. The firm has a market cap of $1.72 billion, a P/E ratio of -19.67 and a beta of 3.01. The firm has a 50-day moving average price of $38.10 and a two-hundred day moving average price of $38.87. Sionna Therapeutics has a 52-week low of $10.97 and a 52-week high of $46.46.

Sionna Therapeutics (NASDAQ:SION) last posted its quarterly earnings results on Monday, March 2nd. The company reported ($0.46) EPS for the quarter, beating the consensus estimate of ($0.61) by $0.15. On average, equities analysts expect that Sionna Therapeutics will post -2.44 EPS for the current year.

Insider Buying and Selling at Sionna Therapeutics

In other Sionna Therapeutics news, Director Peter A. Thompson sold 235,863 shares of the stock in a transaction on Wednesday, April 15th. The stock was sold at an average price of $44.64, for a total value of $10,528,924.32. Following the sale, the director directly owned 3,247,025 shares of the company’s stock, valued at $144,947,196. This trade represents a 6.77% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Orbimed Advisors Llc sold 235,863 shares of the stock in a transaction on Wednesday, April 15th. The stock was sold at an average price of $44.64, for a total value of $10,528,924.32. Following the completion of the sale, the director directly owned 3,247,025 shares in the company, valued at $144,947,196. This represents a 6.77% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 1,193,762 shares of company stock worth $53,594,505 over the last 90 days. 3.90% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of SION. Eventide Asset Management LLC acquired a new position in shares of Sionna Therapeutics during the fourth quarter valued at $26,290,000. Vanguard Group Inc. increased its holdings in shares of Sionna Therapeutics by 81.4% during the third quarter. Vanguard Group Inc. now owns 1,143,154 shares of the company’s stock valued at $33,620,000 after purchasing an additional 512,803 shares during the period. State Street Corp increased its holdings in shares of Sionna Therapeutics by 188.7% during the fourth quarter. State Street Corp now owns 693,395 shares of the company’s stock valued at $28,526,000 after purchasing an additional 453,196 shares during the period. Viking Global Investors LP increased its holdings in shares of Sionna Therapeutics by 8.2% during the second quarter. Viking Global Investors LP now owns 3,195,181 shares of the company’s stock valued at $55,436,000 after purchasing an additional 242,427 shares during the period. Finally, Millennium Management LLC increased its holdings in shares of Sionna Therapeutics by 1,425.5% during the third quarter. Millennium Management LLC now owns 214,085 shares of the company’s stock valued at $6,296,000 after purchasing an additional 200,051 shares during the period.

About Sionna Therapeutics

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.